HCPCS code J9039: Blinatumomab, per 1 mcg2026 Medicare rate & RVUs in California

CMS doesn’t publish an office rate for J9039 in California.

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J9039 covers

Blinatumomab is a bispecific antibody used to treat B-cell precursor acute lymphoblastic leukemia. It engages T cells to target malignant B cells and is typically administered by continuous intravenous infusion using a pump. Oncology teams provide and manage the infusion in hospital or outpatient settings; treatment may also involve a portable pump for ongoing infusion outside the clinic.

J9039 represents 1 microgram of blinatumomab, so report units according to the micrograms administered. CMS excludes this code from the physician fee schedule under status E. When Medicare covers the drug, it generally pays through the Part B drug method using CMS’s quarterly Average Sales Price files; coverage is left to the Medicare contractor’s judgment. The drug code identifies the medication, while the applicable infusion or pump service is reported separately when appropriate.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J9039 pays more and less in California

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

29 of 29 payment localities

How the J9039 rate is calculated

Each of J9039’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J9039

J9039 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J9039 compared with similar codes

How to choose

J9026Tarlatamab injectionPer 1 mg

J9026 identifies tarlatamab-dlle per 1 milligram, a different drug. J9039 identifies blinatumomab per 1 microgram.

J9038Axatilimab injectionPer 0.1 mg

J9038 identifies axatilimab-csfr in 0.1-milligram units. It is not the blinatumomab drug code.

J9042Brentuximab vedotinPer 1 mg

J9042 identifies brentuximab vedotin, a different antineoplastic drug. Use J9039 for blinatumomab.

Codes related to J9039

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates